Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GenVec - GNVC -- Ignore unavailable to you. Want to Upgrade?

To: Savant who wrote (30)	5/13/2011 12:33:58 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 106

Should GNVC get a partnership for either TNFerade, RSV, or Dengue Fever Vaccines it's very possible that the up front payment could make them cash positive for the year. With the R/S cutting the O/S to 13 million, such a payment could dramatically move the stock. For now we're still roughly $1 below where we'd been if no R/S had been done, I cannot call it a complete success until at least that much is recaptured without any real news. At this point, however, I'd concede this R/S has been more successful then about 90% of the one's I've seen. I believe the company has a viable business plan, now they must execute it. Gary